Shattuck Labs (NASDAQ:STTK – Get Free Report) issued its earnings results on Thursday. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01, Zacks reports. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%.
Shattuck Labs Stock Performance
Shattuck Labs stock traded down $0.04 during trading on Thursday, hitting $1.14. The company’s stock had a trading volume of 143,597 shares, compared to its average volume of 377,103. The stock has a market capitalization of $54.42 million, a price-to-earnings ratio of -0.75 and a beta of 1.66. The stock’s fifty day moving average is $1.24 and its 200 day moving average is $1.51. Shattuck Labs has a 1-year low of $0.94 and a 1-year high of $11.76.
Wall Street Analyst Weigh In
STTK has been the topic of several recent research reports. Leerink Partners initiated coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They set an “outperform” rating and a $4.00 price target on the stock. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a report on Thursday. Finally, HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a research note on Thursday. Four analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.50.
Shattuck Labs Company Profile
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Featured Stories
- Five stocks we like better than Shattuck Labs
- The 3 Best Fintech Stocks to Buy Now
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to SellÂ
- How is Compound Interest Calculated?
- Top 3 Beverage Stocks Pouring Out Profits
- What Are the U.K. Market Holidays? How to Invest and Trade
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
